{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-24-000002","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.332988+00:00","generated_at":"2026-06-07T04:18:01.416751+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mineralys Therapeutics appoints Minji Kim Ph.D. as CBO; splits CFO/CBO roles","bullets":["Adam Levy remains CFO and Secretary; no longer serves as CBO as of Jan 4, 2024.","Dr. Kim brings >20 years biotech BD experience including Jounce Therapeutics and Curis.","Company expects clinical milestones for hypertension drug lorundrostat over next 12–18 months.","Role split supports expanded operations as Mineralys advances late-stage development."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-24-000002","json":"https://secwatch.observer/filing/0001933414-24-000002.json","markdown":"https://secwatch.observer/filing/0001933414-24-000002.md","text":"https://secwatch.observer/filing/0001933414-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/0001933414-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/mlys-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:18:01.416751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"723536ac9a","claim":"Adam Levy changed role as Chief Business Officer at Mineralys Therapeutics, Inc..","evidence_excerpt":"As a result, effective January 4, 2024, Adam Levy no longer serves as the Company’s Chief Business Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/0001933414-24-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"no longer serves as"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"bee016d10f","claim":"Minji Kim was appointed as Chief Business Officer at Mineralys Therapeutics, Inc..","evidence_excerpt":"On January 4, 2024, in connection with the appointment of Minji Kim, Ph.D., as Chief Business Officer, the Board of Directors of Mineralys Therapeutics, Inc. (the “Company”) approved splitting the functions of Chief Financial Officer and Chief Business Officer into two roles.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000002/0001933414-24-000002-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}